What are the limitations of the irecist?

While the irecist is highly validated, it should not replace clinical judgment. OpiCalc provides the latest evidence-based limitations for the irecist to ensure safe bedside use and optimal diagnostic accuracy.

How does the irecist compare to other Oncology scores?

The irecist is a gold-standard diagnostic tool. OpiCalc provides side-by-side clinical guidance to help clinicians choose the most specific evidence-based tool for their patient's presentation.

Is the irecist free to use?

Yes. OpiCalc provides the irecist completely ad-free and optimized for mobile bedside use, ensuring you can calculate medical risk swiftly and without distraction.

iRECIST

Tumour Response Assessment

Immunotherapy-adapted RECIST response assessment.

Percent change in target lesion sum

New lesion or PD threshold met

Progression confirmed on subsequent scan

Complete disappearance of disease

Waiting For Required Inputs

Complete the required fields to generate the oncology interpretation.

EVIDENCE SYNTHESIS

Clinical Reference Hub

Curated insights • How it Works • Practical Pearls • Evidence Base

CLINICAL INSIGHT

When to Use

Primary Use

Immunotherapy-adapted RECIST response assessment.

CLINICAL INSIGHT

How it Works

Clinical Inputs

Percent change in target lesion sum

New lesion or PD threshold met

Progression confirmed on subsequent scan

Complete disappearance of disease

CLINICAL INSIGHT

Practical Pearls

Result Bands

CLINICAL INSIGHT

Next Steps

Suggested Next Steps

Interpret the result in the full disease-specific clinical context.
Correlate with pathology, imaging, performance status, and multidisciplinary guidance.

CLINICAL INSIGHT

Evidence Base

Immunotherapy-adapted RECIST response assessment.

OpiCalc Medical Oncology ModuleTumour Response Assessment2026

CLINICAL INSIGHT

Background

Context

iRECIST is included in the oncology module as a structured decision-support tool for tumour response assessment workflows.

No clinical reference data available.

iRECIST

Tumour Response Assessment

Immunotherapy-adapted RECIST response assessment.

Percent change in target lesion sum

New lesion or PD threshold met

Progression confirmed on subsequent scan

Complete disappearance of disease

Waiting For Required Inputs

Complete the required fields to generate the oncology interpretation.

EVIDENCE SYNTHESIS

Clinical Reference Hub

Curated insights • How it Works • Practical Pearls • Evidence Base

CLINICAL INSIGHT

When to Use

Primary Use

Immunotherapy-adapted RECIST response assessment.

CLINICAL INSIGHT

How it Works

Clinical Inputs

Percent change in target lesion sum

New lesion or PD threshold met

Progression confirmed on subsequent scan

Complete disappearance of disease

CLINICAL INSIGHT

Practical Pearls

Result Bands

CLINICAL INSIGHT

Next Steps

Suggested Next Steps

Interpret the result in the full disease-specific clinical context.
Correlate with pathology, imaging, performance status, and multidisciplinary guidance.

CLINICAL INSIGHT

Evidence Base

Immunotherapy-adapted RECIST response assessment.

OpiCalc Medical Oncology ModuleTumour Response Assessment2026

CLINICAL INSIGHT

Background

Context

iRECIST is included in the oncology module as a structured decision-support tool for tumour response assessment workflows.

No clinical reference data available.